Expression of matrix metalloproteinases in patients with Wegener’s granulomatosis

V Bjerkeli, B Halvorsen, J K Damás, I Nordøy, A Yndestad, P Aukrust, S S Frøland

Background: Enhanced activity of matrix metalloproteinases (MMPs) has been reported to have a pathogenic role in several diseases such as cancer and cardiovascular disorders, and seems also to play a part in certain autoimmune diseases. 

Objective: To examine whether enhanced MMP activity may also have a role in the pathogenesis of Wegener’s granulomatosis (WG).

Methods: In a study group of 15 patients with WG and 15 controls, plasma levels and gene expression were measured in freshly isolated peripheral blood mononuclear cells (PBMCs) of several MMPs and their endogenous inhibitors (that is, tissue inhibitors of metalloproteinases (TIMPs)) by enzyme immunoassays and RNase protection assay, respectively.

Results: Whereas patients with WG in remission had enhanced gene expression of several MMPs and TIMPs in PBMCs, those with active disease had a selective up regulation of MMP-2 and MMP-8 compared with healthy controls, and a down regulation of TIMP-1 and TIMP-3 compared with other patients with WG. Moreover, plasma levels of TIMP-1 and MMP-8 correlated significantly with C reactive protein levels, further supporting an association between activation of the MMP/TIMP system and disease activity in WG. Finally, these changes in MMP/TIMP expression in WG were accompanied by increased total MMP activity in PBMC supernatants, particularly in those with active disease, suggesting a matrix degrading net effect.

Conclusion: These findings suggest that disturbed MMP and TIMP activity has a role in the pathogenesis of WG.

PATIENTS AND METHODS

Patients and controls

A total of 15 patients, seven men and eight women, with generalised WG were included in the study (table 1). All patients fulfilled the American College of Rheumatology 1990 classification criteria and the Chapel Hill Consensus Conference on the Nomenclature of Systemic Vasculitis 1992 definition for WG. Twelve (80%) of the patients had biopsy confirmed WG with necrotising vasculitis, granulomatous inflammation, or both, in one or more organ systems. In the three patients in whom WG could not be confirmed histologically, the diagnosis was made on the basis of the typical history, characteristic clinical findings, and a positive classic antineutrophil cytoplasmic antibody test with specificity for proteinase-3. Patients with WG were classified as having active disease or as being in remission based on clinical judgment, the Birmingham Vasculitis Activity Score (BVAS), as well as levels of C reactive protein (CRP) and the erythrocyte sedimentation rate (ESR). For comparison, blood samples were also obtained from 15 healthy controls matched for age and sex. Informed consent for blood sampling was obtained from all subjects. The study was conducted following the ethical guidelines at our hospital according to the Helsinki declaration and was approved by the hospital’s authorised representative.

Abbreviations: BVAS, Birmingham Vasculitis Activity Score; CRP, C reactive protein; ECM, extracellular matrix; EIA, enzyme immunoassay; ESR, erythrocyte sedimentation rate; MMP, matrix metalloproteinase; PBMC, peripheral blood mononuclear cell; RPA, RNase protection assay; TIMP, tissue inhibitor of matrix metalloproteinase; WG, Wegener’s granulomatosis
Blood sampling protocol
Peripheral venous blood was drawn into pyrogen-free tubes without additives (serum) or with EDTA as anticoagulant (plasma). The tubes were immediately immersed in melting ice and centrifuged (1500 g for 10 minutes) within 20 minutes (plasma) or allowed to clot before centrifugation (serum). All samples were stored at \(-80^\circ\text{C}\) and thawed only once.

Isolation and culturing of cells
Peripheral blood mononuclear cells (PBMCs) were obtained from heparinised blood by Isopaque-Ficoll (Lymphoprep, Nycomed Pharma, Oslo, Norway) gradient centrifugation within 45 minutes. For mRNA analyses (see below), cell pellets were stored in liquid nitrogen until used for RNA extraction. For analyses of MMP activity, PBMCs (2 \(\times 10^6\) /ml, 1 ml/well) were incubated in flat bottomed, 24 well microtitre plates (Costar, Cambridge, MA) with serum-free medium (X-vivo; Bio-Whittaker, Walkersville, MD). After different times, cell-free supernatants were removed and stored at \(-80^\circ\text{C}\).

RNase protection assay (RPA)
Total RNA was extracted from PBMCs using RNeasy columns (Qiagen, Hilden, Germany) and stored in RNA storage solution (Ambion, Austin, TX) at \(-80^\circ\text{C}\). RPA was performed as previously described using the hMMP-2 multiprobe (Pharmingen, San Diego, CA).

Zymography
Gelatinase activity was detected in PBMC supernatant after incubation for 18 hours, as previously described. Briefly, 46 \(\mu\)g of protein was incubated with a sample buffer containing 2% sodium dodecyl sulphate. Human pro-MMP-9 and active MMP-9 (Oncogene, Cambridge, MA) were run in a separate lane to ensure identification of MMP activity. Gels were scanned by Kodak 440 CF imaging station (Vector, Burlingame, CA), and the software Total Laboratory (Phoretix, Newcastle, UK) was used for quantification.

Total MMP activity
Total MMP activity in PBMC supernatants was measured by a fluorogenic peptide substrate (R&D systems, Minneapolis, MN; cat no: ES001) using the protocol recommended by the manufacturer. Briefly, the MMP substrate was diluted in TCN buffer (50 mM Tris HCl, 150 mM NaCl, 10 mM CaCl2; pH 7.5) and added to the supernatants (preactivated by aminophenylmercuric acetate (Sigma, St Louis, MO) for 1 hour) before incubation at 37°C. After 30 minutes the total MMP activity was determined on a fluorimeter (FLX 800 Microplate Fluorescence Reader; Bio-Tek Instruments, Winooski, VT).

Table 1
Characteristics of the patients with WG

<table>
<thead>
<tr>
<th>Patient No</th>
<th>Sex</th>
<th>Age (years)</th>
<th>Disease activity</th>
<th>C reactive protein (mg/l)</th>
<th>ESR (mm/1st h)</th>
<th>Drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Male</td>
<td>27</td>
<td>Remission</td>
<td>8</td>
<td>7</td>
<td>IVIg</td>
</tr>
<tr>
<td>2</td>
<td>Female</td>
<td>65</td>
<td>Remission</td>
<td>&lt;5</td>
<td>9</td>
<td>Pred 10 mg qd</td>
</tr>
<tr>
<td>3</td>
<td>Male</td>
<td>41</td>
<td>Remission</td>
<td>10</td>
<td>21</td>
<td>Pred 10 mg qd</td>
</tr>
<tr>
<td>4</td>
<td>Male</td>
<td>33</td>
<td>Remission</td>
<td>&lt;5</td>
<td>18</td>
<td>Pred 5 mg qd</td>
</tr>
<tr>
<td>5</td>
<td>Female</td>
<td>31</td>
<td>Remission</td>
<td>&lt;5</td>
<td>18</td>
<td>TMP/SMX</td>
</tr>
<tr>
<td>6</td>
<td>Female</td>
<td>52</td>
<td>Remission</td>
<td>5</td>
<td>8</td>
<td>-</td>
</tr>
<tr>
<td>7</td>
<td>Male</td>
<td>59</td>
<td>Remission</td>
<td>5</td>
<td>17</td>
<td>TMP/SMX</td>
</tr>
<tr>
<td>8</td>
<td>Female</td>
<td>37</td>
<td>Remission</td>
<td>&lt;5</td>
<td>11</td>
<td>Pred 10 mg qd</td>
</tr>
<tr>
<td>9</td>
<td>Female</td>
<td>35</td>
<td>Active</td>
<td>14</td>
<td>110</td>
<td>Pred 20 mg bid, CYC</td>
</tr>
<tr>
<td>10</td>
<td>Male</td>
<td>28</td>
<td>Active</td>
<td>29</td>
<td>61</td>
<td>Pred 15 mg qd, CYC</td>
</tr>
<tr>
<td>11</td>
<td>Female</td>
<td>58</td>
<td>Active</td>
<td>161</td>
<td>100</td>
<td>Pred 15 mg qd, etan</td>
</tr>
<tr>
<td>12</td>
<td>Female</td>
<td>84</td>
<td>Active</td>
<td>45</td>
<td>53</td>
<td>Pred 20 mg bid, CYC</td>
</tr>
<tr>
<td>13</td>
<td>Female</td>
<td>56</td>
<td>Active</td>
<td>62</td>
<td>96</td>
<td>Pred 20 mg bid, CYC</td>
</tr>
<tr>
<td>14</td>
<td>Female</td>
<td>35</td>
<td>Active</td>
<td>57</td>
<td>30</td>
<td>Pred 20 mg bid, IVIg</td>
</tr>
<tr>
<td>15</td>
<td>Male</td>
<td>58</td>
<td>Active</td>
<td>16</td>
<td>47</td>
<td>Pred 20 mg bid, CYC</td>
</tr>
</tbody>
</table>

ESR, erythrocyte sedimentation rate; Pred, prednisolone; IVIg, intravenous immunoglobulin; TMP/SMX, trimetroprim/sulfamethoxazole; CYC, cyclophosphamide; etan, etanercept; bid, twice a day; qd, every day.

Figure 1
Gene expression (RPA) of MMPs in relation to the control gene rpL32 in PBMCs from patients with WG classified as being in remission (n = 8) (A) or as having active disease (n = 7) (B) according to the BVAS, serum levels of CRP, and ESR (see table 1) and 15 healthy controls. Data are given as mean (SEM). *p<0.01 and **p<0.001 versus healthy controls.
Matrix metalloproteinases in Wegener’s granulomatosis

and were considered significant when Spearman’s rank correlation test. Values of p were two-sided test. Relationships between variables were tested using the Mann-Whitney rank sum test. Statistical comparisons between patients with WG and healthy controls and between different groups of patients with WG were performed using the Mann-Whitney rank sum test. Data are given as mean (SEM). *p<0.01 and **p<0.001 versus active disease and healthy controls.

Enzyme immunoassays (EIAs)

Plasma concentrations of MMP-3, MMP-8, and TIMP-1 were quantified by EIAs (R&D System). MMP-2 levels were analysed by EIA (Amersham Biosciences, Buckinghamshire, UK). The intra- and interassay coefficients of variation were 10% for all EIAs.

Statistical analysis

Statistical comparisons between patients with WG and healthy controls and between different groups of patients with WG were performed using the Mann-Whitney rank sum test. Relationships between variables were tested using Spearman’s rank correlation test. Values of p were two-sided and were considered significant when <0.05.

RESULTS

Gene expression levels of MMPs and TIMPs

We first analysed the gene expression of several MMPs and TIMPs in PBMCs from patients with WG (n = 15) and healthy controls (n = 15). Figure 1 shows that while several MMPs (that is, MMP-1, MMP-2, MMP-3, MMP-12, and MMP-14) were moderately up regulated in patients with WG in remission, those with active disease showed a different pattern, with a selective and marked up regulation of MMP-2 (p<0.01) and MMP-8 (p<0.01) compared with gene expression in healthy controls. Furthermore, whereas patients with WG in remission had increased expression of TIMP-1 and TIMP-3 compared with healthy controls, such an up regulation was not seen in patients with active disease. In fact, TIMP-1 and TIMP-3 were significantly down regulated in those with active disease compared with other patients with WG (fig 2).

Plasma levels of MMPs and TIMPs

To further examine the MMP/TIMP system in WG, we examined plasma levels of MMP-2, MMP-3, MMP-8, and TIMP-1, all shown to be dysregulated in WG at the mRNA levels (see above), in 15 patients with WG and 15 healthy controls. Figure 2 shows that patients with WG had enhanced plasma levels of MMP-2, MMP-3, and TIMP-1 compared with healthy controls. Moreover, when the patients with WG were classified as having active disease (n = 7) or being in remission (n = 8) (table 1), we found that those with active disease had raised plasma levels of MMP-3, MMP-8, and TIMP-1 compared with the other patients with WG, although the difference for MMP-8 (p = 0.053) did not reach significance (fig 4). Moreover, plasma levels of TIMP-1 and MMP-8, but not MMP-2 and MMP-3, correlated significantly with CRP levels in the patient group as a whole (fig 5).

MMP activity

To examine if this altered MMP and TIMP expression resulted in any changes in MMP activity, we first measured total MMP activity in PBMC supernatants from nine patients with WG (five in remission and four with active disease) and eight healthy controls. Figure 6 shows that the substrate used in this assay can be cleaved by MMP-1, MMP-2, MMP-7, MMP-8, MMP-9, MMP-12, and MMP-13. The changes in MMP and TIMP expression in WG were accompanied by a significant increase in total MMP activity, particularly in
those with active disease (data not shown), suggesting a matrix degrading net effect. Moreover, because MMP-9 was not included in the RPA probe, we analysed MMP-9 activity by zymography in PBMC supernatants from six patients with WG and six healthy controls. Comparable to total MMP activity, patients with WG had increased MMP-9 activity both for the pro-enzyme (94 kDa) and for its active form (84 kDa) (fig 6).

**DISCUSSION**

In this study we report that patients with WG are characterised by marked alterations in gene expression of several MMPs and TIMPs in PBMCs. Whereas patients with WG in remission had moderately enhanced expression of several MMPs and TIMPs, those with active disease had a selective and marked up regulation of MMP-2 and MMP-8 compared with healthy controls, and a down regulation of TIMP-1 and TIMP-3 compared with other patients with WG. Finally, these changes in MMP/TIMP expression in WG were accompanied by increased total MMP activity in PBMC supernatants, particularly in those with active disease, indicating a matrix degrading net effect. Although we cannot exclude the possibility that some of these findings may reflect the use of immunosuppressive drugs in the patient group, our results suggest a role for disturbed MMP/TIMP activity in the pathogenesis of WG.

MMPs are a pivotal family of zinc enzymes responsible for degradation of the ECM components.\(^7\) In this study we show that PBMCs from patients with WG have markedly enhanced expression of several MMPs with the potential to induce degradation of tissue components such as collagen, fibronectin, and various proteoglycans.\(^7\) Notably, patients with WG with active disease were characterised by a selective and marked up regulation of MMP-2 and MMP-8 and, as for MMP-8, such an association with disease activity was also found for plasma levels. Among collagenases, MMP-8 most effectively hydrolyses the native type I and II collagens.\(^16\) It has been suggested that this MMP has a pathogenic role in disorders such as chronic bronchiectasis, cystic fibrosis, and rheumatoid arthritis.\(^7\) \(^16\) \(^17\) and although we have no data on MMP-8 enzymatic activity, our results suggest that this MMP also may also play a part in the pathogenesis of WG.

The activity of MMPs is regulated by several factors such as the levels of their naturally occurring inhibitors (for example, TIMPs).\(^7\) \(^8\) Although the increase in MMP levels was accompanied by enhanced expression of TIMP-1 and TIMP-3 in patients with WG in remission, this was not found in those with active disease. Such an imbalance between MMPs and their endogenous inhibitors was also indicated at the functional level, showing enhanced total MMP activity in patients with WG, particularly in those with active disease. While patients with active disease showed no increase in TIMP-1 gene expression in PBMCs, these patients had raised plasma levels of this inhibitor. The reasons for these apparently discrepant results are at present not clear but several possibilities exist. Firstly, plasma levels of TIMP-1 will not only reflect the production in PBMCs but also other cells, such as endothelial cells and tissue macrophages, may be of even more importance. Moreover, while the TIMP-1 level in PBMCs reflects the actual TIMP-1 expression in this cell population, plasma levels of TIMP-1 may also be regarded as a measure of the activity in the TIMP/MMP system.\(^7\) \(^9\) \(^18\)

Several studies have shown potent induction of MMP expression by inflammatory cytokines such as tumour necrosis factor \(\alpha\), interleukin 12, and chemokines.\(^7\) \(^8\) \(^15\) \(^20\) Because a number of reports have shown increased levels of such inflammatory cytokines in WG,\(^3\) \(^4\) \(^20\) it is not inconceivable that cytokine induced MMP activity may also be operating in this disorder. Whatever the mechanisms, this disturbed MMP/TIMP expression in WG with net ECM degrading effects may have several pathogenic consequences. Thus, studies in animal models suggest that enhanced MMP activity may promote tissue destruction, remodelling, and fibrosis in the lungs.\(^17\) \(^22\) \(^23\) Moreover, recent studies in rat models suggest the involvement of MMP-2 and MMP-14 in the pathogenesis of crescentic glomerulonephritis.\(^24\) Furthermore, although the role of MMPs in various nasal

---

**Figure 5**  Correlation between plasma levels of CRP and MMP-8 (A) and TIMP-1 (B) in 15 patients with WG.

**Figure 6**  MMP activity in PBMC supernatants from patients with WG and healthy controls. (A) Total MMP activity in nine patients with WG and eight healthy controls using a fluorogenic peptide substrate (see “Patients and methods”). (B) Gelatinolytic (MMP-9) activity in PBMC supernatants after incubation for 18 hours in two representative patients with WG and two healthy controls. Gelatinolytic activity was seen as lytic bands and the majority of these were identified as pro-MMP-9 and active MMP-9. Note: pro-MMP-9 was only detected in the WG group. RFU, relative fluorescence units.
disorders is largely unclear, enhanced MMP activity seems to play a part in the pathogenesis of nasal polyps and allergic rhinitis,\textsuperscript{25–26} and even more importantly with relevance to WG, several MMPs (for example, MMP-1, MMP-3, and MMP-8) have been shown to promote degradation of type II collagen and proteoglycan in nasal cartilages.\textsuperscript{27–28} Finally, while inflammatory cytokines are potent inducers of MMPs, enhanced MMP activity may itself promote inflammation and granuloma formation, representing a possible link between tissue destruction/remodelling and inflammation in various disorders.\textsuperscript{29} Unbalanced MMP activity has been demonstrated in several disorders, such as arthritis, malignancies, and arteriosclerosis, and although not specific for WG, our demonstration of a correlation between MMP/TIMP levels and disease activity, as assessed by both clinical and laboratory criteria, suggests that such a pathogenic link may also be operating in WG. Although these findings will have to be confirmed also at the tissue level, particularly in target organs, our results suggest that WG may be added to this list of disorders characterised by dysregulated MMP/TIMP levels, possibly representing a new target for treatment in this disorder.

ACKNOWLEDGEMENTS
This work was supported by the Research Council of Norway, the Norwegian Cancer Society, and Medinnova Foundation. We thank Ellen Lund Sagen, Bodil Lundén, and Azita Rashidi for excellent technical assistance.

*Authors’ affiliations*
V Bjerkeli, B Halvorsen, J K Damás, A Yndestad, P Aukrust, S S Frøland, Research Institute for Internal Medicine, Medical Department, Rikshospitalet University Hospital, N-0027 Oslo, Norway
I Nordøy, P Aukrust, S S Frøland, Section of Clinical Immunology and Infectious Diseases, Medical Department, Rikshospitalet University Hospital, N-0027 Oslo, Norway

*REFERENCES*
Expression of matrix metalloproteinases in patients with Wegener's granulomatosis

V Bjerkeli, B Halvorsen, J K Damås, I Nordøy, A Yndestad, P Aukrust and S S Frøland

doi: 10.1136/ard.2003.017954

Updated information and services can be found at:
http://ard.bmj.com/content/63/12/1659

These include:

References
This article cites 28 articles, 7 of which you can access for free at:
http://ard.bmj.com/content/63/12/1659#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Immunology (including allergy) (5144)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/